BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Net Income & Profit History
Annual & trailing net income, net margin, YoY change, and peer profitability context.
BBIO · net income · updated Jun 8, 2026
Core profitability metrics
BBIO · net income · margin · TTM · CAGRNet income was −$729.3M for FY2025 (fiscal year ending 2025-12-31), down 36.1% year-over-year. Net profit margin was -145.3%.
Annual net income history
▸ FMP /income-statement · Annual · BBIO net income history · BBIO profit margin
Annual net income data
Net income vs peers (Healthcare)
About Net Income & Methodology
BridgeBio Pharma, Inc. (BBIO) reported net income of −$729.3M for FY2025 (fiscal year ending 2025-12-31), down 36.1% year-over-year. The net profit margin was -145.3% — meaning the company kept $-1.45 of every dollar of revenue as profit.
BridgeBio Pharma, Inc. has not yet achieved annual profitability based on available data (9 fiscal years). The company has reported net losses across all available periods.
BridgeBio Pharma, Inc.'s net profit margin was -145.3% for FY2025, based on the latest annual results.
Investors sometimes search for "BridgeBio Pharma, Inc. net worth" — the company's market capitalization is a separate figure from BBIO net income. Data sourced from FMP /income-statement · US GAAP · USD.
Frequently asked questions
BBIO net income · 4 questionsBridgeBio Pharma, Inc. is not currently profitable on an annual basis. The company reported a net loss of $729.3M for FY2025.
▸ Source: FMP /income-statement · GAAP · BridgeBio Pharma, Inc. · BridgeBio Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026